Alternatives to animal testing are finally taking off
Points and comments are a snapshot, not live.
New rules and technologies are shifting drug testing from animals to human-cell systems.
Donald Ingber's lung-on-a-chip, developed at Harvard's Wyss Institute, was initially rejected by Science but is now part of a broader shift. The FDA Modernization Act 2.0 and a 2026 FDA rule allow alternatives like organs-on-chips and computer models. Emulate's liver-on-a-chip flagged 7/8 drugs toxic to humans. Thomas Hartung says the transition is more about change management than technology. Validation remains a challenge, with studies requiring 870 chips and 16 full-time staff.
What commenters are saying
Commenters broadly welcome the shift, citing high failure rates and animal suffering. Many note animal testing is already a pain for researchers and not cheap. A tiered approach is advocated: avoid animals when possible, minimize harm, and treat survivors well. Some argue current standards are mere formalities, with millions killed annually. Others point out that human trials remain necessary and carry their own risks, citing the TeGenero disaster. A split exists between those urging faster adoption and those stressing biological complexity.